Thrombosis and Haemostasis 2021 Editors' Choice Papers

This year's Editor's Choice highlights the 2021 manuscripts published in Thrombosis and Haemostasis and its open access companion journal TH Open that found most resonance within our academic community. As in the precedent year, the 2021 COVID-19 pandemic situation has dictated the pace and direction of our research and clinical management efforts which, although not exclusively, is well reflected by this years' Editor's Choice contents.[1] [2] [3] [4]

At the end of 2020, we published a Theme Issue dedicated to COVID-19 as a guide to better comprehend newly identified vascular and inflammatory mechanistic aspects of the disease,[5] its hypercoagulation state,[6] and clinical implications for vascular patients with COVID-19.[7] [8] To address the rapidly evolving situation and following a first consensus paper,[9] we were pleased to publish an interesting discussion manuscript by the VAS investigators on the need for a more integrated and global strategy to COVID-19, providing a useful overview of public health approaches consideration and the next steps necessary to best manage the pandemic.[10] While research efforts throughout 2020 focused on characterizing the coagulation abnormalities observed in COVID19 patients giving cues to the next clinical approaches to adopt, the results from such strategies mostly came out in the following year 2021.

Publication History

Received: 02 December 2021

Accepted: 02 December 2021

Article published online:
17 January 2022

• References

• 1 Lip GYH, Rigby A, Weber C. A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!. Thromb Haemost 2020; 120 (01) 1-4
• 2 Lip GYH, Rigby A, Weber C. Looking Back on 2020, Looking Forward to 2021. Thromb Haemost 2021; 121 (01) 1-3
• 3 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2019 Editor's Choice Papers. Thromb Haemost 2020; 120 (01) 184-190
• 4 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2020 Editors' Choice Papers. Thromb Haemost 2021; 121 (01) 109-114
• 5 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020; 120 (12) 1629-1641
• 6 Katneni UK, Alexaki A, Hunt RC. et al. Coagulopathy and thrombosis as a result of severe COVID-19 infection: a microvascular focus. Thromb Haemost 2020; 120 (12) 1668-1679
• 7 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020; 120 (12) 1642-1653
• 8 Waite AAC, Hamilton DO, Pizzi R, Ageno W, Welters ID. Hypercoagulopathy in severe COVID-19: implications for acute care. Thromb Haemost 2020; 120 (12) 1654-1667
• 9 Gerotziafas GT, Catalano M, Colgan M-P. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
• 10 Gerotziafas GT, Catalano M, Theodorou Y. et al; Scientific Reviewer Committee. The COVID-19 pandemic and the need for an integrated and equitable approach: an international expert consensus paper. Thromb Haemost 2021; 121 (08) 992-1007
• 11 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120 (12) 1691-1699
• 12 Di Castelnuovo A, Costanzo S, Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST Study. Thromb Haemost 2021; 121 (08) 1054-1065
• 13 Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG. et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost 2021; 121 (07) 944-954
• 14 Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost 2021; 121 (01) 76-85
• 15 Bikdeli B, Talasaz AH, Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost 2021;
• 16 Cohen SL, Gianos E, Barish MA. et al; Northwell Health COVID-19 Research Consortium. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost 2021; 121 (08) 1043-1053
• 17 Goldin M, Giannis D, Diab W. et al. Treatment-dose LMWH versus prophylactic/intermediate dose heparins in high-risk COVID-19 inpatients: rationale and design of the HEP-COVID trial. Thromb Haemost 2021; 121 (12) 1684-1695
• 18 Spyropoulos AC, Goldin M, Giannis D. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181 (12) 1612-1620
• 19 Fumagalli S, Trevisan C, Del Signore S. et al. COVID-19 and atrial fibrillation in older patients: does oral anticoagulant therapy provide a survival benefit?—an insight from the GeroCovid Registry. Thromb Haemost 2021;
• 20 Mycroft-West CJ, Su D, Pagani I. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the Spike S1 receptor-binding domain with heparin. Thromb Haemost 2020; 120 (12) 1700-1715
• 21 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020; 120 (05) 876-878
• 22 Valerio L, Ferrazzi P, Sacco C. et al; Humanitas COVID-19 Task Force. Course of D-dimer and C-reactive protein levels in survivors and nonsurvivors with COVID-19 pneumonia: a retrospective analysis of 577 patients. Thromb Haemost 2021; 121 (01) 98-101
• 23 Sjöström A, Wersäll JD, Warnqvist A. et al. Platelet count rose while D-dimer levels dropped as deaths and thrombosis declined—an observational study on anticoagulation shift in COVID-19. Thromb Haemost 2021; 121 (12) 1610-1621
• 24 Bauer W, Galtung N, Neuwinger N. et al. A matter of caution: coagulation parameters in COVID-19 do not differ from patients with ruled-out SARS-CoV-2 infection in the emergency department. TH Open 2021; 5 (01) e43-e55
• 25 Chaudhary R, Kreutz RP, Bliden KP, Tantry US, Gurbel PA. Personalizing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry. Thromb Haemost 2020; 120 (11) 1594-1596
• 26 Hammer S, Häberle H, Schlensak C. et al. Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: a descriptive study of fibrinolysis in COVID-19. Thromb Haemost 2021; 121 (11) 1417-1426
• 27 Słomka A, Kowalewski M, Żekanowska E. Hemostasis in coronavirus disease 2019-lesson from viscoelastic methods: a systematic review. Thromb Haemost 2021; 121 (09) 1181-1192
• 28 Hardy M, Michaux I, Dive A, Lecompte T, Mullier F. Could daily monitoring of fibrin related markers help suspect a thrombotic event in COVID-19 patients? A prospective pilot study. TH Open 2021; 5 (02) e152-e154
• 29 Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Low ADAMTS13 activity correlates with increased mortality in COVID-19 patients. TH Open 2021; 5 (01) e89-e103
• 30 Léopold V, Pereverzeva L, Schuurman AR. et al. Platelets are hyperactivated but show reduced glycoprotein VI reactivity in COVID-19 patients. Thromb Haemost 2021; 121 (09) 1258-1262
• 31 Ghirardello S, Lecchi A, Artoni A. et al. Assessment of platelet thrombus formation under flow conditions in adult patients with COVID-19: an observational study. Thromb Haemost 2021; 121 (08) 1087-1096
• 32 Violi F, Ceccarelli G, Loffredo L. et al. Albumin supplementation dampens hypercoagulability in COVID-19: a preliminary report. Thromb Haemost 2021; 121 (01) 102-105
• 33 Pape A, Kielstein JT, Krüger T, Fühner T, Brunkhorst R. Treatment of a critically ill COVID-19 patient with the Seraph 100 Microbind Affinity Filter. TH Open 2021; 5 (02) e134-e138
• 34 Elalamy I, Gerotziafas G, Alamowitch S. et al; Scientific Reviewer Committee. SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia. Thromb Haemost 2021; 121 (08) 982-991
• 35 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
• 36 Vayne C, Nguyen TH, Rollin J. et al. Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. Thromb Haemost 2021; 121 (03) 322-331
• 37 Warkentin TE. Heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: fraternal—not identical—twins. Thromb Haemost 2021; 121 (12) 1558-1561
• 38 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021; 121 (12) 1622-1627
• 39 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
• 40 Weber C, von Hundelshausen P, Siess W. VITT after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 385: 2202-2205
• 41 Harenberg J, Marchetti M, Falanga A. Acquired autoimmune hemophilia following SARS-CoV-2 vaccines: dual-drug effects on blood coagulation and the Scylla and Charybdis phenomenon. Thromb Haemost 2021; 121 (12) 1555-1557
• 42 Farley S, Ousley R, Van Wagoner N, Bril F. Autoimmunity after coronavirus disease 2019 (COVID-19) vaccine: a case of acquired hemophilia A. Thromb Haemost 2021; 121 (12) 1674-1676
• 43 Potpara TS, Lip GYH, Blomstrom-Lundqvist C. et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. Thromb Haemost 2021; 121 (03) 270-278
• 44 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost 2021; 123 (01) 20-47
• 45 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
• 46 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2021;
• 47 Lip GYH, Ntaios G. “Novel Clinical Concepts in Thrombosis”: integrated care for stroke management-easy as ABC. Thromb Haemost 2021;
• 48 Field M, Kuduvalli M, Torella F, McKay V, Khalatbari A, Lip GYH. Integrated care systems and the aortovascular hub. Thromb Haemost 2021;
• 49 Sun W, Freedman B, Martinez C, Wallenhorst C, Yan BP. Atrial fibrillation detected by single time-point handheld electrocardiogram screening and the risk of ischemic stroke. Thromb Haemost 2021;
• 50 Proietti M, Boriani G. Screening for atrial fibrillation in relation to stroke and mortality risk. Thromb Haemost 2021;
• 51 Wallenhorst C, Martinez C, Freedman B. Risk of ischemic stroke in asymptomatic atrial fibrillation incidentally detected in primary care compared with other clinical presentations. Thromb Haemost 2021;
• 52 Wachter R, Freedman B. Subclinical atrial fibrillation and the risk of recurrent ischemic stroke. Thromb Haemost 2021; 121 (06) 697-699
• 53 Kitsiou A, Rogalewski A, Kalyani M. et al. Atrial fibrillation in patients with embolic stroke of undetermined source during 3 years of prolonged monitoring with an implantable loop recorder. Thromb Haemost 2021; 121 (06) 826-833
• 54 Nelson AJ, Johnston BW, Waite AAC, Lemma G, Welters ID. A systematic review of anticoagulation strategies for patients with atrial fibrillation in critical care. Thromb Haemost 2021; 121 (12) 1599-1609
• 55 Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C, Sloop S. Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms. Thromb Haemost 2021;
• 56 Jones NR, Crawford W, Yang Y, Hobbs FDR, Taylor CJ, Petrou S. A systematic review of economic aspects of service interventions to increase anticoagulation use in atrial fibrillation. Thromb Haemost 2021;
• 57 Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: the Murcia AF Project. Thromb Haemost 2020; 120 (08) 1200-1207
• 58 Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Marín F, Lip GYH. Stroke and thromboembolism in warfarin-treated patients with atrial fibrillation: comparing the CHA2DS2-VASc and GARFIELD-AF risk scores. Thromb Haemost 2021; 121 (08) 1107-1114
• 59 de Vries TAC, Hirsh J, Xu K. et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?-a systematic review. Thromb Haemost 2020; 120 (09) 1323-1329
• 60 Chao T-F, Guo Y. Should we adopt a standard international normalized ratio range of 2.0 to 3.0 for Asian patients with atrial fibrillation? An appeal for evidence-based management, not eminence-based recommendations. Thromb Haemost 2020; 120 (03) 366-368
• 61 Pandey AK, Xu K, Zhang L. et al. Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost 2020; 120 (03) 484-494
• 62 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
• 63 Choi SY, Kim MH, Lee KM. et al. Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: a nationwide population-based study. Thromb Haemost 2021; 121 (09) 1151-1160
• 64 Chang PY, Wang W, Wu WL. et al. Oral anticoagulation timing in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 2021;
• 65 Pandey AK, Eikelboom JW. Direct oral anticoagulant dosing in extremes of body weight: time to revisit the guidelines?. Thromb Haemost 2021; 121 (02) 118-120
• 66 Martin AC, Thomas W, Mahir Z. et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost 2021; 121 (02) 224-233
• 67 Boriani G, Ruff CT, Kuder JF. et al. Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial. Thromb Haemost 2021; 121 (02) 140-149
• 68 Edlmann E, McMahon C. Balancing risks and benefits when recommencing oral anticoagulants after major bleeding. Thromb Haemost 2021; 121 (08) 979-981
• 69 Milling Jr TJ, King B, Yue P. et al; ANNEXA-4 Investigators. Restart of anticoagulant therapy and risk of thrombosis, rebleeding, and death after factor Xa inhibitor reversal in major bleeding patients. Thromb Haemost 2021; 121 (08) 1097-1106
• 70 Douxfils J, Adcock DM, Bates SM. et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2021; 121 (08) 1008-1020
• 71 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
• 72 Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thromb Haemost 2020; 120 (02) 314-321
• 73 Abrahami D, Renoux C, Yin H, Fournier JP, Azoulay L. The association between oral anticoagulants and cancer incidence among individuals with nonvalvular atrial fibrillation. Thromb Haemost 2020; 120 (10) 1384-1394
• 74 Falanga A, Gal GL, Carrier M. et al. Management of cancer-associated thrombosis: unmet needs and future perspectives. TH Open 2021; 5 (03) e376-e386
• 75 Atterman A, Friberg L, Asplund K, Engdahl J. Atrial fibrillation, oral anticoagulants, and concomitant active cancer: benefits and risks. TH Open 2021; 5 (02) e176-e182
• 76 Cohen A, Keshishian A, Lee T. et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost 2021; 121 (03) 383-395
• 77 Ageno W, Vedovati MC, Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021; 121 (05) 616-624
• 78 Jerjes-Sánchez C, Rodriguez D, Farjat AE. et al; GARFIELD-VTE investigators. Pregnancy-associated venous thromboembolism: insights from GARFIELD-VTE. TH Open 2021; 5 (01) e24-e34
• 79 Lecumberri R, Jiménez L, Ruiz-Artacho P. et al; RIETE investigators. Prediction of major bleeding in anticoagulated patients for venous thromboembolism: comparison of the RIETE and the VTE-BLEED scores. TH Open 2021; 5 (03) e319-e328
• 80 Solari D, Alberio L, Ribi C, Grandoni F, Stalder G. Autoimmune hemolytic anemia and pulmonary embolism: an association to consider. TH Open 2021; 5 (01) e8-e13
• 81 Valeriani E, Di Nisio M, Riva N. et al. Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Thromb Haemost 2021; 121 (07) 867-876
• 82 Sokou R, Piovani D, Konstantinidi A. et al. A risk score for predicting the incidence of hemorrhage in critically ill neonates: development and validation study. Thromb Haemost 2021; 121 (02) 131-139
• 83 Guedeney P, Collet J-P. Antithrombotic therapy in acute coronary syndromes: current evidence and ongoing issues regarding early and late management. Thromb Haemost 2021; 121 (07) 854-866
• 84 Jeong Y-H, Oh J-H, Yoon H-J. et al. Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial. Thromb Haemost 2021; 121 (10) 1376-1386
• 85 Liesner RJ, Abraham A, Altisent C. et al. Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect Study. Thromb Haemost 2021; 121 (11) 1400-1408
• 86 Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost 2020; 120 (10) 1357-1370
• 87 Cortesi PA, Castaman G, Trifirò G. et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost 2020; 120 (02) 216-228
• 88 Schmitt C, Adamkewicz JI, Xu J. et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 Study. Thromb Haemost 2021; 121 (03) 351-360
• 89 Budnick IM, Davis JPE, Sundararaghavan A. et al. Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically ill cirrhosis patients. Thromb Haemost 2021; 121 (10) 1317-1325
• 90 Aliotta A, Bertaggia Calderara D, Zermatten MG, Alberio L. Sodium-calcium exchanger reverse mode sustains dichotomous ion fluxes required for procoagulant COAT platelet formation. Thromb Haemost 2021; 121 (03) 309-321
• 91 Ya F, Li K, Chen H. et al. Protocatechuic acid protects platelets from apoptosis via inhibiting oxidative stress-mediated PI3K/Akt/GSK3β signaling. Thromb Haemost 2021; 121 (07) 931-943
• 92 Belleville-Rolland T, Leuci A, Mansour A. et al. Role of membrane lipid rafts in MRP4 (ABCC4) dependent regulation of the cAMP pathway in blood platelets. Thromb Haemost 2021; 121 (12) 1628-1636
• 93 Hally KE, Parker OM, Brunton-O'Sullivan MM, Harding SA, Larsen PD. Linking neutrophil extracellular traps and platelet activation: a composite biomarker score for predicting outcomes after acute myocardial infarction. Thromb Haemost 2021; 121 (12) 1637-1649
• 94 Bouvier S, Fortier M, Vincent L. et al. NETosis markers in pregnancy: effects differ according to histone subtypes. Thromb Haemost 2021; 121 (07) 877-890
• 95 Locke M, Longstaff C. Extracellular histones inhibit fibrinolysis through noncovalent and covalent interactions with fibrin. Thromb Haemost 2021; 121 (04) 464-476
• 96 Stojkovic S, Wadowski PP, Haider P. et al. Circulating microRNAs and monocyte-platelet aggregate formation in acute coronary syndrome. Thromb Haemost 2021; 121 (07) 913-922
• 97 Garcia A, Dunoyer-Geindre S, Nolli S, Strassel C, Reny JL, Fontana P. miR-204-5p and platelet function regulation: insight into a mechanism mediated by CDC42 and GPIIbIIIa. Thromb Haemost 2021; 121 (09) 1206-1219
• 98 Moon MJ, Peter K. MicroRNAs as biomarkers for personalized antiplatelet therapy. Thromb Haemost 2021; 121 (09) 1121
• 99 Garcia A, Dunoyer-Geindre S, Fish RJ, Neerman-Arbez M, Reny JL, Fontana P. Methods to investigate miRNA function: focus on platelet reactivity. Thromb Haemost 2021; 121 (04) 409-421